NCT03619044
Breast Cancer Type: HER2+
Hormone Mutations:
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Not Applicable
Drug Category: Other
Key Eligibility Criteria:
Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes: Patient must be eligible according to the investigator for a treatment with trastuzumab/Herceptin + pertuzumab/Perjeta + taxane (Taxol) in the metastatic first line setting
Exclusions: Patients NOT affiliated to a Social Health Insurance in France; Patients with any previous treatment for metastatic disease
https://ClinicalTrials.gov/show/NCT03619044